ADC Therapeutics Q1 2024 Adj EPS $(0.38) Beats $(0.56) Estimate, Sales $18.053M Miss $18.102M Estimate
ADC Therapeutics Q1 2024 Adj EPS $(0.38) Beats $(0.56) Estimate, Sales $18.053M Miss $18.102M Estimate
ADC Therapeutics 2024年第一季度调整后每股收益美元（0.38）超过预期（0.56），销售额为1,8053万美元，低于预期的1,810.2万美元
ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.56) by 32.14 percent. The company reported quarterly sales of $18.053 million which missed the analyst consensus estimate of $18.102 million by 0.27 percent. This is a 4.94 percent decrease over sales of $18.992 million the same period last year.
ADC Therapeutics（纽约证券交易所代码：ADCT）公布的季度亏损为每股0.38美元，比分析师普遍预期的0.56美元（0.56美元）高出32.14％。该公司公布的季度销售额为1,805.3万美元，比分析师普遍预期的1,810.2万美元低0.27％。这比去年同期的1899.2万美元的销售额下降了4.94％。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。